60.Issue 01 january 25 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 12, Issue : 01, January – 2025

Title:

ATOPIC DERMATITIS

Authors :

Gauri G. Mankar, janvi P. Joshi , Aditi V. Tikait , Swati P. Deshmukh

Abstract :

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition that affects individuals of all ages but is particularly prevalent in children. Characterized by intense itching, dryness, and recurring eczematous lesions, AD significantly impacts patients’ quality of life. Although the exact etiology of AD is not fully understood, it is widely accepted to result from a combination of genetic, environmental, immunological, and skin barrier factors. Mutations in the FLG gene, which codes for the protein filaggrin, disrupt the skin barrier, making individuals more susceptible to allergens and infections. Immune dysregulation, including heightened T-helper 2 (Th2) responses, also plays a crucial role in disease pathogenesis.
Recent advances in research have led to the development of targeted therapies, including biologics such as dupilumab, which inhibit specific immune pathways and have shown promising results in moderate to severe cases. Additionally, new insights into the microbiome’s role in AD have opened avenues for treatments aimed at restoring microbial balance on the skin. Conventional treatments, such as topical corticosteroids and calcineurin inhibitors, remain the cornerstone for mild to moderate AD management but have limitations in efficacy and safety with long-term use.

Cite This Article:

Please cite this article in press Gauri G. Mankar et al., Atopic Dermatitis.,Indo Am. J. P. Sci, 2025; 12 (01).

Number of Downloads : 10

References:

1. Eichenfield LF, Tom WL, Berger EM, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51.Doi:10.1016/j.jaad.2013.10.010.
2. Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2016;2:16001. Doi:10.1038/nrdp.2016.1.
3. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-94. Doi:10.1056/NEJMra074237.
4. National Institutes of Health (NIH). The NIH provides educational materials that often include labeled diagrams of skin layers.
5. Elias PM. Stratum corneum defensive functions: An integrated view. J Dermatol. 2005;20(5):321-9.
6. Rawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level: An update in relation to the dry skin cycle. J Invest Dermatol Symp Proc. 2005;10(3):282-6.
7. Proksch E, Brandner JM, Jensen JM. The skin: An indispensable barrier. Exp Dermatol. 2008;17(12):1063-72.
8. Rawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level: An update in relation to the dry skin cycle. J Invest Dermatol Symp Proc. 2005;10(3):282-6.
9. Elias PM. Stratum corneum defensive functions: An integrated view. J Dermatol. 2005;20(5):321-9
10.uziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. J ARawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level: An update in
relation to the dry skin cycle. J Invest Dermatol Symp Proc. 2005;10(3):282-6.
11.Eichenfield LF, et al. Guidelines of care for the management of atopic
dermatitis. J Am Acad Dermatol. 2014;70(2):338-51.
12.Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769-79.
13.Boguniewicz M, Leung DY. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46.
14.Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-94.
15.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
16.Eyerich K, Eyerich S. Immune response patterns in non-communicableinflammatory skin diseases and their modulation by extracorporeal photopheresis. Eur J Dermatol. 2015;25(6):523-33.
17.Pson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48.
18.Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2017;139(4):1150-61
19.Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48.
20.Barbarot S, Am Acad Dermatol. 2018;78(4):975-83.
21.Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann NutrMetab. 2015;66(Suppl 1):8-16.
22.Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population-based study. Dermatitis. 2014;25(3):107-14.
23.Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3-16.
24.Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769-79.
25.Brown SJ, McLean WH. One remarkable molecule: Filaggrin. J Invest Dermatol. 2012;132(3):751-62.
26.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
27.Silverberg JI, Garg NK. Quality-of-life measurements in atopic dermatitis. Clin Dermatol. 2015;33(3):313-9.
28.Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population-based study. Dermatitis. 2014;25(3):107-114.
29.Silverberg JI, Garg NK. Quality-of-life measurements in atopic dermatitis. Clin Dermatol. 2015;33(3):313-9.
30.Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: Summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.